Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma
- PMID: 25841462
- DOI: 10.3978/j.issn.2304-3865.2014.07.02
Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma
Abstract
Mucosal melanomas arise from melanocytes located at various mucosal membranes, which demonstrate a clear demographic and ethnic disparity. This subtype of melanoma has more aggressive course and poorer prognosis than other subsets of melanomas. Due to their rarity, there is no well-established protocol of staging and treatment of mucosal melanomas. Significant advances have been achieved in novel immunotherapeutic and specific targeted agents for metastatic melanomas. For mucosal melanoma patients especially without known gene mutation, anti-angiogenic therapy combined with chemotherapy or other targeted drugs has shown promising efficacy, either as first- or second-line treatment. In some subset analysis, patients with mucosal melanoma, harboring wild type BRAF, might get more clinical and survival benefits than cutaneous ones. Therefore it is rational to further study these therapeutic strategies in the group of mucosal melanoma. Chemotherapy or biochemotherapy only showed limited efficacy without significant survival improvement, but larger sample size study is still required. Herein we presented a comprehensive review of chemotherapy/biochemotherapy and anti-vascular endothelial growth factor (anti-VEGF) therapy in metastatic mucosal melanoma.
Keywords: Mucosal melanoma; anti-vascular endothelial growth factor therapy (anti-VEGF); chemotherapy.
Similar articles
-
Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.J Immunotoxicol. 2008 Apr;5(2):201-7. doi: 10.1080/15476910802131519. J Immunotoxicol. 2008. PMID: 18569391
-
Management of melanomas of the gynaecological tract.Curr Opin Oncol. 2014 Sep;26(5):508-13. doi: 10.1097/CCO.0000000000000104. Curr Opin Oncol. 2014. PMID: 25046205 Review.
-
[Primitive malignant melanoma of the base of the tongue].Acta Otorhinolaryngol Ital. 1996 Aug;16(4):371-4. Acta Otorhinolaryngol Ital. 1996. PMID: 9082832 Italian.
-
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.Cancer J Sci Am. 2000 Feb;6 Suppl 1:S15-20. Cancer J Sci Am. 2000. PMID: 10685653 Clinical Trial.
-
Mucosal melanomas.Surg Clin North Am. 2003 Apr;83(2):237-52. doi: 10.1016/S0039-6109(02)00100-7. Surg Clin North Am. 2003. PMID: 12744608 Review.
Cited by
-
Primary Malignant Melanoma of the Genitourinary System: A Systemic Review and Report of Eight Cases.Cureus. 2022 Oct 18;14(10):e30444. doi: 10.7759/cureus.30444. eCollection 2022 Oct. Cureus. 2022. PMID: 36407184 Free PMC article. Review.
-
Advances in Immunotherapy for Melanoma: A Comprehensive Review.Mediators Inflamm. 2017;2017:3264217. doi: 10.1155/2017/3264217. Epub 2017 Aug 1. Mediators Inflamm. 2017. PMID: 28848246 Free PMC article. Review.
-
Evolving Treatment Approaches to Mucosal Melanoma.Curr Oncol Rep. 2022 Oct;24(10):1261-1271. doi: 10.1007/s11912-022-01225-z. Epub 2022 May 5. Curr Oncol Rep. 2022. PMID: 35511393 Review.
-
Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma.Biology (Basel). 2021 Dec 31;11(1):54. doi: 10.3390/biology11010054. Biology (Basel). 2021. PMID: 35053051 Free PMC article. Review.
-
Predictive factors for immunotherapy in melanoma.Ann Transl Med. 2015 Sep;3(15):208. doi: 10.3978/j.issn.2305-5839.2015.05.07. Ann Transl Med. 2015. PMID: 26488004 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Research Materials
